Amarna raises €10M to push gene therapy platform into clinic; Editas Medicine, AskBio join forces
→ Amarna Therapeutics — developing an SV40-based gene delivery vector platform called SVac — has raised €10 million. The round was led by Swedish investment company Flerie Invest AB, along with contributions from the Netherlands Enterprise Agency and existing shareholder Pim Berger. The funds will be used to develop SVac and steer it into a first-in-man clinical study, expected to commence in the coming years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.